| # | Title | Journal | Year | Citations |
|---|
| 1 | Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study | Lancet Oncology, The | 2016 | 723 |
| 2 | Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 | JAMA Oncology | 2022 | 719 |
| 3 | Genetics of Follicular Lymphoma Transformation | Cell Reports | 2014 | 471 |
| 4 | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Blood | 2013 | 420 |
| 5 | Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma | Cancer Cell | 2015 | 378 |
| 6 | The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development | Journal of Experimental Medicine | 2012 | 363 |
| 7 | The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia | World Psychiatry | 2014 | 346 |
| 8 | Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge | JAMA Network Open | 2021 | 336 |
| 9 | Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis | Lancet, The | 2015 | 321 |
| 10 | Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia | Blood | 2014 | 302 |
| 11 | Comparison of Reliability, Validity, and Responsiveness of the Mini-BESTest and Berg Balance Scale in Patients With Balance Disorders | Physical Therapy | 2013 | 289 |
| 12 | Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature | European Urology | 2015 | 274 |
| 13 | Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia | Blood | 2012 | 257 |
| 14 | Recurrent mutations refine prognosis in chronic lymphocytic leukemia | Leukemia | 2015 | 253 |
| 15 | Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma | Blood | 2018 | 223 |
| 16 | Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia | JAMA Psychiatry | 2018 | 214 |
| 17 | Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome | Blood | 2013 | 208 |
| 18 | COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus | Leukemia | 2020 | 198 |
| 19 | Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia | Blood | 2015 | 197 |
| 20 | The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia | Haematologica | 2013 | 195 |
| 21 | Diffuse large B-cell lymphoma genotyping on the liquid biopsy | Blood | 2017 | 183 |
| 22 | ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia | Leukemia | 2012 | 182 |
| 23 | Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial | Lancet Oncology, The | 2014 | 164 |
| 24 | Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer | Cancer Discovery | 2020 | 151 |
| 25 | Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA | Nature Biotechnology | 2021 | 151 |
| 26 | Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia | Cancer | 2014 | 149 |
| 27 | A MALT lymphoma prognostic index | Blood | 2017 | 149 |
| 28 | ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation | Leukemia | 2018 | 149 |
| 29 | The genetics of nodal marginal zone lymphoma | Blood | 2016 | 147 |
| 30 | Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation | JAMA - Journal of the American Medical Association | 2019 | 143 |
| 31 | Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial | Lancet Oncology, The | 2016 | 142 |
| 32 | Molecular pathogenesis of chronic lymphocytic leukemia | Journal of Clinical Investigation | 2012 | 138 |
| 33 | Biology and treatment of Richter syndrome | Blood | 2018 | 138 |
| 34 | Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction | Cell | 2019 | 138 |
| 35 | Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi | Annals of Oncology | 2014 | 133 |
| 36 | Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations | Blood | 2016 | 130 |
| 37 | Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study | Lancet Oncology, The | 2015 | 129 |
| 38 | Osteopontin at the Crossroads of Inflammation and Tumor Progression | Mediators of Inflammation | 2017 | 129 |
| 39 | The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi | Annals of Oncology | 2013 | 124 |
| 40 | Eye tracking communication devices in amyotrophic lateral sclerosis: Impact on disability and quality of life | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | 2013 | 123 |
| 41 | Breast Cancer Survivorship, Quality of Life, and Late Toxicities | Frontiers in Oncology | 2020 | 121 |
| 42 | Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia | Blood | 2013 | 113 |
| 43 | Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2) | Hepatology | 2019 | 111 |
| 44 | Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia | Proceedings of the National Academy of Sciences of the United States of America | 2017 | 108 |
| 45 | Outcomes of music therapy interventions in cancer patients—A review of the literature | Critical Reviews in Oncology/Hematology | 2019 | 108 |
| 46 | Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19 | Journal of Perinatal Medicine | 2020 | 107 |
| 47 | Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi | Lancet Haematology,the | 2017 | 106 |
| 48 | Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma | Annals of Oncology | 2018 | 106 |
| 49 | Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics | MAbs | 2013 | 105 |
| 50 | Universal school-based prevention for illicit drug use | The Cochrane Library | 2017 | 105 |
